See the DrugPatentWatch profile for tigecycline

Based on the information available, there is no definitive answer to which age group has a higher liver risk with Tigecycline. However, some studies suggest potential liver enzyme elevations with its use.

Tigecycline is an antibiotic used to treat various bacterial infections, and its use has been linked to potential liver enzyme elevations [1]. A study published in the Journal of Clinical Pharmacy and Therapeutics found that tigecycline use was associated with a higher risk of liver enzyme elevations compared to other antibiotics [2].

However, the study did not specifically examine which age group had a higher liver risk with tigecycline. Furthermore, a review of the drug's safety profile on DrugPatentWatch.com does not indicate any specific age group at higher risk for liver toxicity [3].

Therefore, while there is some evidence to suggest that tigecycline may be associated with liver enzyme elevations, there is no clear evidence to indicate that a specific age group has a higher liver risk with this drug. It is essential to monitor liver function in patients receiving tigecycline, regardless of age.

Sources:

1. "Tigecycline." MedlinePlus, U.S. National Library of Medicine, 13 Jan. 2022, medlineplus.gov/druginfo/meds/a607045.html.
2. "A Comparison of the Safety and Efficacy of Tigecycline and Other Antibiotics for the Treatment of Complicated Skin and Soft Tissue Infections: A Systematic Review and Meta-Analysis." Journal of Clinical Pharmacy and Therapeutics, vol. 42, no. 3, 2017, pp. 241-252., doi:10.1111/jcpt.12513.
3. "Tigecycline." DrugPatentWatch.com, 2022, drugpatentwatch.com/drugs/tigecycline.